Advertisement
Screener

CARDIFF ONCOLOGY, INC. (CRDF) Lessee, Operating Lease, Liability, to be Paid, after Year Five

2.0 / 5 stars · 44/111 Roast Me

CARDIFF ONCOLOGY, INC. Lessee, Operating Lease, Liability, to be Paid, after Year Five

CARDIFF ONCOLOGY, INC. (CRDF) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $136.00 thousand as of 2021-12-31, per its 10-K filed 2022-02-24.

Discontinued › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity

us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2022-02-24

  • 2021-12-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $136.00K.
Period endLessee, Operating Lease, Liability, to be Paid, after Year Five
2021-12-31$136.00K
10-K · filed 2022-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Vaxart, Inc. (VXRT)United States$0.080B3.84
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B